Teva Targets Risperidone LAI In H1 2023 Following Earlier FDA Snub

505(b)(2) Hybrid Risperidone Long-Acting Injectable Given Name Uzedy

 
• By Dean Rudge
  
Target
Teva is targeting a H1 2023 launch • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Value Added Medicines

More from Products